Declined vitamin D may be a trigger for hemifacial spasm

Aim: In this study, we aimed to measure the serum vitamin D levels in Hemifacial Spasmic (HFS) patients and show the role of HFS in the pathogenesis and place in etiology.Material and Methods: In this study, prospective 80 HFS patients and 80 healthy volunteers who were followed up at neurology clinic were prospectively included. The serum vitamin D levels of the patient and the control group with similar age, gender, and body mass index (BMI) was measured on the same day. The severity of the disease was measured using Jeong’s Quality of Life Scale and correlated with vitamin D concentration. The results were compared using the independent t test and the Mann-Whitney U test.Results: Serum vitamin D levels in patients with HFS were 16.4 [9 - 30.4] ng / ml in the patient group and 21.8 [9 - 42.6] ng / ml in the control group, and this difference was statistically significant (p

PDF

___

Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve 1998;21:1740-7
Batla A, Goyal C, Shukla G, et al. Hemifacial spasm: clinical characteristics of 321 Indian patients. J Neurol 2012;259:1561-65.
Auger RG, Whisnant J. Hemifacial spasm in Rochester and Olmstead County, Minnesota, 1960 to 1984. Arch Neurol 1990:47;1233-4.
Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol 2012;34:47-64.
Harms LR, Burne TH, Eyles DW, et al. Vitamin D and the brain. Best Pract Res Clin Endocrinol Metab 2011;25:657-69.
Deluca GC, Kimball SM, Kolasinski J, et al. The Role of Vitamin D in nervous system health and disease. Neuropathol Appl Neurobiol 2013;39:458-84.
Nielsen VK, Pathophysiology of hemifacial spasm: I. Ephaptic transmission and ectopic excitation. Neurology 1984;34:418-26.
Hatem J, Sindou M, Vial C. Intraoperative monitoring of facial EMG responses during microvascular decompression for hemifasial spasm. Prognostic value fo long-term outcome: a study in a 33-patient series. Br J Neurosurg 2001;15:496-9.
Colosimo C, Bologna M, Lamberti S, et al. A comparative study of primary and secondary hemifacial spasm. Arch Neurol 2006;63:441-4.
Fraga CG. Relevance, essentiality and toxicity of trace elements in human health. Mol Aspects Med 2005;26:235-44.
Alizadeh A, Mehrpour O, Nikkhah K, et al. Comparison of serum concentration of Se, Pb, Mg, Cu, Zn, between MS patients and healthy controls. Electron Physician 2016;8:2759-64.
Campbell E, Keedy C. Hemifacial spasm: a note on the etiology in two cases. J Neurosurg 1947;4:342-47.
Lee JA, Jo KW, Kong DS, et al. Using the new clinical grading scale for quantification of the severity of hemifacial spasm: correlations with a quality of life scale. Stereotact Funct Neurosurg 2012;90:16-9.
Auger RG, Whisnant JP. Hemifacial spasm in Rochester and Olmstead County, Minnesota, 1960 to 1984. Arch Neurol 1990:47;1233-34.
Miller LE, Miller VM. Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review. Br J Neurosurg 2012;26:438 44.
Tan EK, Chan LL, Lim SH, et al. Role of Magnetic resonance imaging and magnetic resonance angiography in patients with hemifacial spasm. Ann Acad Med Singapore 1999:28;169-73.
Karp BI, Alter K. Botulinum toxin treatment of blepharospasm, orofacial/oromandibular dystonia, and hemifacial spasm. Semin Neurol 2016:36;84-91.
De Ridder D, Møller A, Verlooy J, et al. Is the root entry/exit zone important in microvascular compression syndromes? Neurosurgery 2002;51:427-33.
Davies BE. Trace elements in the human environment: problems and risks. Environ Geochem Health 1994;16:97-106.
Frei K, Truong DD, Dressler D. Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations. Eur J Neurology 2006;13:30-5.
da Silva Martins WC, de Albuquerque LAF, de Carvalho GTC, Tenth case of bilateral hemifacial spasm treated by microvascular decompression: Review of the pathophysiology. Surg Neurol Int 2017;8:225.
Evatt ML, Delong MR, Khazai N, et al. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008;65:1348-52.
Taniura H, Ito M, Sanada N, et al. Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J Neurosci Res 2006;83:1179-89.
Tokucoglu F, Sucu HK, Celebisoy M, et al. Hemifacial spasm in correlation with electrophysiological and radiological findings. Acta Neurol Belg 2008;108:94-8.
Sanchez B, Relova JL, Gallego R, et al. 1,25-Dihy¬droxyvitamin D3 administration to 6-hydroxydopa¬mine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hy¬droxylase expression in substantia nigra and striatum. J Neurosci Res 2009;87:723-32.
Dörr J, Döring A, Paul F. Can we prevent or treat multiple sclerosis by individualized vitamin D supply? EPMA J 2013:29;4:4.
de Rezende Pena C, Grillo LP, das Chagas Medeiros MM. Evaluationof 25-hydroxyvitamin D serum levels in patients with fibromyalgia. J Clin Rheumatol 2010;16:365-9.
Ding XD, Chen HX, Xiao HQ, et all. Efficiency of ultrasound and water capsule-guided local injection of botulinum toxin type a treatment on patients with facial spasm. Eur Rev Med Pharmacol Sci. 2015;19:1837-41.